Catalyst Event
Daewoong Pharmaceutical Co Ltd (069620) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
5/12/2026, 12:00:00 AM
On May 12, 2026, the company announced a license-in and co-development agreement with Innovo Therapeutics for the IBD drug candidate 'INV-008'. The total deal size is up to KRW 662.5 billion, including an upfront payment of KRW 6.5 billion.
Korean Translation
2026년 5월 12일 이노보테라퓨틱스로부터 염증성 장질환(IBD) 치료제 후보물질 'INV-008'을 도입하는 기술도입 및 공동개발 계약을 체결함. 총 계약 규모는 최대 6,625억원이며, 이 중 계약금은 65억원임.
Related Recent Events
SK Biopharmaceuticals Co Ltd (326030) · Other
SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.
5/29/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
Q1 2026 earnings release on 2026-05-18 with high price impact expected based on results versus expectations scheduled.
5/18/2026, 12:00:00 AM
Voronoi Inc (310210) · Other
Corporate briefing (IR) for domestic and international institutional investors to explain company status scheduled; 1% price impact as IR sessions typically have limited immediate market reaction analysts estimated.
5/18/2026, 12:00:00 AM
OliX Pharmaceuticals Inc (226950) · Other
CEO Dong Ki Lee is scheduled to present research on the company's RNAi platform for ophthalmic diseases at the TIDES USA 2026 conference on May 14, 2026; a 5% price impact is estimated due to potential clinical data updates, scheduled.
5/14/2026, 12:00:00 AM
HK inno N Corporation (195940) · Other
Announced on May 13, 2026, that its blockbuster drug 'K-CAB' became the top-prescribed drug in Korea for April 2026, with monthly outpatient prescription sales of KRW 20.8 billion.
5/13/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Earnings Release
Daewoong Pharmaceutical announced its Q1 2026 earnings on May 12, 2026. On a separate basis, revenue was KRW 335.7 billion (+6.2% YoY) while operating profit was KRW 27.4 billion (-34.7% YoY).
5/12/2026, 12:00:00 AM